quetiapine extended-release / Generic mfg. - LARVOL DELTA

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression. (PubMed, J Comp Eff Res) - "Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK NS + OAD) versus quetiapine extended release plus an oral antidepressant (QTP XR + OAD) among adults with treatment-resistant depression (TRD). Under the scenario analysis, the cost-per-remitter for ESK NS + OAD compared with QTP XR + OAD was $15,133.66 lower in the commercial setting and $12,487.62 lower in the Medicaid setting. The findings suggest that ESK NS + OAD is a cost-effective treatment for adults with TRD compared with QTP XR + OAD in the commercial and Medicaid settings."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Adverse events associated with four atypical antipsychotics used as augmentation treatment for major depressive disorder: A pharmacovigilance study based on the FAERS database. (PubMed, J Affect Disord) - "It is suggesting a potential increased risk of various ADEs in patients with MDD when taking AAPs. The causal relationship and the exact mechanism between drugs and ADEs remains unclear, requiring further research."

Adverse events • Journal • Cardiovascular • CNS Disorders • Depression • Glaucoma • Inflammation • Major Depressive Disorder • Mental Retardation • Metabolic Disorders • Mood Disorders • Movement Disorders • Obsessive-Compulsive Disorder • Ophthalmology • Psychiatry • Restless Legs Syndrome • Sleep Disorder

SMART-BD: Sequential Multiple Assignment Randomized Trial for Bipolar Depression (clinicaltrials.gov) - P4 | N=2726 | Recruiting | Sponsor: Massachusetts General Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis. (PubMed, BMC Psychiatry) - "Holistically considering each endpoint and corresponding "time window", certain SGAs appeared to be efficient augmentation to anti-depressants for TRD, but aripiprazole was relatively more effective and better tolerated."

Clinical • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study. (PubMed, Eur Neuropsychopharmacol) - P3 | "Patients receiving esketamine NS experienced greater improvements in functioning and productivity over 32 weeks versus quetiapine XR. These improvements demonstrate the clinical and functional benefit of treatment with esketamine NS for patients with TRD."

Journal • P3 data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression. (PubMed, J Clin Psychiatry) - "By week 32, total WPL decreased from baseline by 45.3 pp and 32.5 pp in the esketamine and quetiapine cohorts (MD = 12.7 pp; 95% CI, 4.7-20.7 pp), with weekly cost savings of $543 and $390 (MD = $153; 95% CI, $57-$250), respectively. Among employed adults with TRD, esketamine treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine, suggesting greater benefits from patient well-being and employer perspectives."

Clinical • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial. (PubMed, CNS Spectr) - No abstract available

Clinical • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial. (PubMed, Br J Psychiatry) - "Esketamine nasal spray consistently demonstrated significant superiority over quetiapine extended release using all pre-specified definitions for remission and relapse. Sensitivity analyses supported the conclusions of the primary ESCAPE-TRD analysis and demonstrated robustness of the results."

Journal • P3 data • CNS Disorders • Depression • Psychiatry

Disease-specific quality of life with esketamine nasal spray versus quetiapine extended release in treatment resistant depression: Results from ESCAPE‑TRD (ECNP 2024) - P3 | "Conclusion :ESK-NS-treated patients experienced significantly greater improvements in HRQoL versus QTP‑XR; more patients reached clinically meaningful improvement and did so in a shorter time. Results suggest the superior clinical efficacy reported for ESK‑NS in ESCAPE-TRD was also perceived by patients, with favourable effects on HRQoL."

HEOR • CNS Disorders • Depression • Mood Disorders • Psychiatry

Treatment patterns of esketamine nasal spray amongst patients with treatment resistant depression in a phase IIIb study: Results from ESCAPE‑TRD (ECNP 2024) - P3 | "Introduction :ESCAPE-TRD (NCT04338321) was a randomised, phase IIIb trial comparing the efficacy and safety of esketamine nasal spray (ESK-NS) versus quetiapine extended release (Q-XR), when both were flexibly dosed alongside an ongoing selective serotonin/serotonin-norepinephrine reuptake inhibitor, in patients with treatment resistant depression (TRD). Of 336 patients randomised to ESK-NS, 334 received ≥1 dose of study treatment.Of 334 ESK-NS-treated patients, 21 (6.3%) and 313 (93.7%) received 28 or 56 mg as the starting dose, respectively. In patients who started at 56 mg, median time to escalation to 84 mg was 21 days (95% confidence interval: 15, 24).The most often administered dosages were 28, 56 and 84 mg for 6 (1.8%), 138 (41.3%) and 189 (56.6%) patients during treatment, respectively. One patient received doses of 56 mg and 84 mg on an equal number of days."

Clinical • P3 data • CNS Disorders • Depression • Mood Disorders • Psychiatry

Pharmacobezoar Associated Prolonged Clinical Course in a Patient with Immediate Release Quetiapine Overdose. (PubMed, J Med Toxicol) - "A massive quetiapine IR overdose with pharmacobezoars can cause a delayed increase in serum quetiapine concentrations."

Journal • CNS Disorders • Depression • Psychiatry

Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial. (PubMed, Psychiatry Investig) - "Lurasidone 160 mg/day was found to be non-inferior to QXR 600 mg/day in the treatment of schizophrenia with comparable efficacy and tolerability. Adverse effects of lurasidone were generally tolerable, and beneficial effects on metabolic parameters can be expected."

Clinical • Journal • CNS Disorders • Dyslipidemia • Psychiatry • Schizophrenia

Case Management Approaches in Patients with Bipolar Disorders and Alcohol Use Disorders (ISBD 2024) - "All patients were initiated on treatment with naltrexone 50 mg/zi, added to their ongoing mood-stabilizer treatment (valproate or carbamazepine +/- quetiapine XR). Adding naltrexone for AUD in patients with type I BD is a useful case management approach in patients with this dual diagnosis."

Clinical • Addiction (Opioid and Alcohol) • Bipolar Disorder • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Personality Disorder • Psychiatry

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression. (PubMed, Eur Neuropsychopharmacol) - P3 | "Data were consistent with established safety profiles, with no new safety signals identified. Alongside greater efficacy, the demonstrably more favourable tolerability profile of esketamine NS versus quetiapine XR further supports its use for TRD."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression. (PubMed, Pharmacopsychiatry) - "The acceptability of both antipsychotics to bipolar depression in clinical practice may be similar. However, specific AEs for each antipsychotic (LUR: akathisia and QUE-ER: somnolence) were associated with high treatment discontinuation."

Journal • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

SMART-BD: Sequential Multiple Assignment Randomized Trial for Bipolar Depression (clinicaltrials.gov) - P4 | N=2726 | Not yet recruiting | Sponsor: Massachusetts General Hospital

New P4 trial • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Update on Treatment Resistant Depression (WFSBP 2024) - "Intravenous ketamine and intranasal esketamine (co-administered with an antidepressant) are established as efficacious in the management of TRD. Several second-generation antipsychotics (e.g., aripiprazole, brexpiprazole, cariprazine, quetiapine XR) are proven effective as antidepressant augmentation treatments in partial responders, but only the olanzapine-fluoxetine combination has been studied in FDA-defined TRD...Non-üphasrmacological treatment options are also available including both psychotherapy as well as ECt or TMS. There is as yet no clear distinction in the algorithm when to place these treatment modalities."

CNS Disorders • Depression • Mood Disorders • Psychiatry

A Randomized, Double-Blind, Active Comparator-Controlled, Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of Ulotaront in Patients with Schizophrenia (ASCP 2024) - "The results of this study extend the findings from a previously-reported 6-month Phase 2 study to 52 weeks [4], demonstrating that long-term treatment with ulotaront is safe and well-tolerated with no unexpected adverse effects for this novel TAAR1 agonist class drug. The notable lack of adverse effects of ulotaront on lipids and glycemic indices, and the significant reduction in weight and waist circumference, are consistent with preclinical research suggesting that ulotaront improves glycemic control and reduces body weight in rodent models of diabetes, obesity, and iatrogenic weight gain [2]. Learning Objectives • Long-term treatment (52-weeks) with ulotaront, an investigational trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A activity, was safe and well-tolerated with no unexpected adverse events in patients with schizophrenia."

Clinical • P3 data • CNS Disorders • Insomnia • Mood Disorders • Psychiatry • Schizophrenia • Sleep Disorder

Post-marketing surveillance of quetiapine fumarate extended-release tablets in patients with bipolar depression. (PubMed, Neuropsychopharmacol Rep) - "The efficacy of quetiapine fumarate extended-release tablets was confirmed in clinical practice, and no new safety concerns or risks were identified."

Journal • P4 data • Bipolar Disorder • CNS Disorders • Constipation • Depression • Gastroenterology • Gastrointestinal Disorder • Mood Disorders • Psychiatry • Sleep Disorder • Suicidal Ideation

Comparative Effectiveness of Intravenous Racemic Ketamine and Intranasal Esketamine in Adults with Treatment Resistant Depression (ASCP 2024) - "In addition, when added to existing antidepressants in adults with TRD, IN esketamine has been shown to be superior to Quetiapine XR in the acute and maintenance treatment of TRD. Effectiveness, tolerability and acceptability will be discussed in what is the largest RWE effectiveness comparison of these aforementioned treatment options. Learning Objectives 1) To discuss a rationale for real world evidence (RWE) comparing IV racemic ketamine to IN esketamine 2) To compare the effectiveness of IV racemic ketamine and IN esketamine in adults with TRD in two real-world international samples"

Clinical • HEOR • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Assessment of Patient-Reported Depression Severity in Subpopulation of Escape-Trd study: Esketamine Nasal Spray Versus Quetiapine for Treatment-Resistant Depression (ASCP 2024) - P3 | "Using the patient-reported PHQ-9 data, esketamine NS significantly increased the proportion of patients achieving remission and response at 8 and 32 weeks, and shortened time to remission and response vs. quetiapine XR in the subgroup. The findings were consistent with the overall study population."

Clinical • CNS Disorders • Depression • Mood Disorders • Psychiatry

Comparing efficacy and safety of Symbyax (olanzapine-fluoxetine), Seroquel XR (quetiapine XR), and Spravato (intranasal esketamine) for treatment-resistant depression: A literature review (AMCP 2024) - No abstract available

Clinical • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

A Randomized, Double-Blind, Active Comparator-Controlled, Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of Ulotaront in Patients With Schizophrenia (SIRS 2024) - "Exploratory analyses were included to compare ulotaront to an atypical antipsychotic (quetiapine XR). In the safety population treated with ulotaront (N=201) and QXR (N=102), total discontinuations were 47.8% vs. 44.1%, respectively, and AEs leading to study discontinuation were 22% vs. 21%."

Clinical • Late-breaking abstract • P3 data • CNS Disorders • Schizophrenia

Weight changes in esketamine nasal spray and quetiapine extended-release treated patients with treatment resistant depression: Results from ESCAPE-TRD study (EPA 2024) - P3 | "Increase in weight was uncommon with ESK-NS; weight increases were more common with QTP-XR and resulted in more treatment discontinuations. Weight increase was independent from baseline BMI."

Clinical • CNS Disorders • Depression • Mood Disorders • Psychiatry

Schizoaffective Disorder and Parkinson's Disease: a case report (EPA 2024) - "As usual treatment, in addition to anticoagulation and antihypertensive therapy, the patient has been receiving L-dopa for his PD for years, antidepressant treatment with escitalopram 10mg, haloperidol 80 drops a day, divided into three doses, and lormetazepam 2mg as a hypnotic... Due to the comorbid neurological pathology, it was decided to progressively modify the treatment, withdrawing the benzodiazepine due to the risk of confusional disorder and replacing it with trazodone. Antipsychotic treatment was gradually replaced by extended-release quetiapine, reaching a maximum dose of 800mg. Likewise, escitalopram treatment is replaced by sertraline... The Spanish Society of Psychogeriatrics recommends that before using antipsychotics, it is advisable to first treat the underlying potentially treatable causes (pain, infections, toxic effects of drugs...), assess non-pharmacological interventions and always, if the use of antipsychotics is required, assess the risk-benefit..."

Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Mood Disorders • Pain • Parkinson's Disease • Psychiatry • Schizophrenia